Literature DB >> 12739017

Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

H F Escobar-Morreale1, G Villuendas, J I Botella-Carretero, J Sancho, J L San Millán.   

Abstract

AIMS/HYPOTHESIS: Increased serum inflammatory markers have been found in obesity and insulin-resistant states, and could play a causative role in insulin resistance, atherosclerosis and cardiovascular disease. The polycystic ovary syndrome represents a human model of insulin resistance because both lean and obese polycystic ovary syndrome patients are insulin-resistant compared with non-hyperandrogenic women. We evaluated whether obesity, insulin resistance, or both, are related to the increased concentrations of inflammatory markers in pre-menopausal women.
METHODS: We compared 35 patients with polycystic ovary syndrome and 28 healthy women, paired for BMI, prevalence of obesity and smoking. Measurements included serum inflammatory markers, BMI, waist-to-hip ratio, blood pressure, serum glucose, insulin, lipid and hormone concentrations, and insulin sensitivity index.
RESULTS: The insulin sensitivity index was reduced in polycystic ovary syndrome patients compared with controls. However, no differences were observed between both groups in C-reactive protein, interleukin 6, tumour necrosis factor-alpha, soluble type 2 tumour necrosis factor receptor, and soluble intercellular cell adhesion molecule-1. When considering patients and controls as a whole, C-reactive protein and interleukin 6, were increased in obese subjects compared with lean women. Inverse correlations existed between insulin sensitivity index and C-reactive protein, interleukin 6, tumour necrosis factor-alpha, soluble type 2 tumour necrosis factor receptor, and soluble intercellular cell adhesion molecule-1. Only the weak correlation with C-reactive protein persisted after controlling for BMI. CONCLUSION/
INTERPRETATION: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739017     DOI: 10.1007/s00125-003-1090-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Interleukin-6: the endocrine cytokine.

Authors:  D A Papanicolaou; A N Vgontzas
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

2.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Authors:  J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 3.  Biologic markers as predictors of cardiovascular disease.

Authors:  W H Frishman
Journal:  Am J Med       Date:  1998-06-22       Impact factor: 4.965

4.  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

Authors:  J M Fernandez-Real; M Vayreda; C Richart; C Gutierrez; M Broch; J Vendrell; W Ricart
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

Review 5.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

6.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  The relation of body fat mass and distribution to markers of chronic inflammation.

Authors:  A Festa; R D'Agostino; K Williams; A J Karter; E J Mayer-Davis; R P Tracy; S M Haffner
Journal:  Int J Obes Relat Metab Disord       Date:  2001-10

8.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

9.  Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism.

Authors:  Belén Peral; José L San Millán; Roberto Castello; Paolo Moghetti; Héctor F Escobar-Morreale
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

10.  Hirsutism: implications, etiology, and management.

Authors:  R Hatch; R L Rosenfield; M H Kim; D Tredway
Journal:  Am J Obstet Gynecol       Date:  1981-08-01       Impact factor: 8.661

View more
  29 in total

1.  Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.

Authors:  M Möhlig; A Flöter; J Spranger; M O Weickert; T Schill; H W Schlösser; G Brabant; A F H Pfeiffer; J Selbig; C Schöfl
Journal:  Diabetologia       Date:  2006-09-14       Impact factor: 10.122

2.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

3.  Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome.

Authors:  Frank González; Neal S Rote; Judi Minium; Amy L Weaver; John P Kirwan
Journal:  Cytokine       Date:  2010-07-03       Impact factor: 3.861

4.  Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.

Authors:  Nina M Clark; Amanda J Podolski; Eric D Brooks; Donna R Chizen; Roger A Pierson; Denis C Lehotay; Marla E Lujan
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

5.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

Review 6.  Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

7.  The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients.

Authors:  M Erdogan; M Karadeniz; A Berdeli; G Alper; O Caglayan; C Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

8.  The inflammatory gene pathway is not a major contributor to polycystic ovary snydrome.

Authors:  Surabhi Bhatt; Priscilla Mutharasan; Obed A Garcia; Nadereh Jafari; Richard S Legro; Andrea Dunaif; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

9.  The abnormal measures of iron homeostasis in pediatric obesity are associated with the inflammation of obesity.

Authors:  Matthew W Richardson; Leybie Ang; Paul F Visintainer; Chrystal A Wittcopp
Journal:  Int J Pediatr Endocrinol       Date:  2009-10-08

10.  Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Agnieszka Nikolajuk; Irina Kowalska; Monika Karczewska-Kupczewska; Agnieszka Adamska; Elzbieta Otziomek; Slawomir Wolczynski; Ida Kinalska; Maria Gorska; Marek Straczkowski
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.